CATALYST PHARMACEUTICALS INC
CPRXNASDAQ🏆 #1419 by market capUS Equity
$31.49▲ $0.00 (+0.00%)
Live1h—
24h▲ 0.0%
7d▲ 0.0%
14d▲ 0.0%
30d▲ 0.0%
1y▲ 54.9%
🏦Market Cap
$3.85B
Small Cap
📈Revenue Growth (YoY)
+19.8%
Healthy
📊Gross Margin
82.3%
High
💵FCF Margin
34.9%
Strong
⚖️P/S Ratio
6.5x
Fair
Otter Score
65
Fair
📊
Analyst Ratings
Price
$31.49
Total
16
Raised
1
Lowered
4
Avg PT
$31.75
H / L
$32 / $32
| Institution | Action | Rating | Date |
|---|---|---|---|
HC Wainwright & Co. | Downgraded | Buy → Neutral | 2026-05-28 |
Citigroup | Downgraded | Buy → Neutral | 2026-05-08 |
Stephens & Co. | Downgraded | Overweight → Equal Weight | 2026-05-07 |
Baird | Reiterated | Outperform | 2025-03-03 |
B of A Securities | Reiterated | Buy | 2025-01-09 |
Truist Securities | Reiterated | Buy | 2024-11-11 |
Oppenheimer | Reiterated | Outperform | 2024-06-06 |
Cantor Fitzgerald | Reiterated | Overweight | 2024-03-22 |
Piper Sandler | Reiterated | Overweight | 2022-12-20 |
Roth Capital | Downgraded | Buy → Neutral | 2022-08-24 |
SunTrust Robinson Humphrey | Reiterated | Buy | 2020-05-13 |
PiperJaffray | Reiterated | Overweight | 2018-12-13 |
MLV & Co. | Reiterated | Buy | 2015-06-24 |
Maxim Group | Reiterated | Buy | 2013-09-24 |
Aegis Capital | Reiterated | Buy | 2013-09-06 |
Rodman & Renshaw | Upgraded | Market Perform → Market Outperform | 2012-08-27 |
One row per institution, most recent rating